



## Correction to: The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients

Angelo Antonini<sup>1</sup> · Giovanni Abbruzzese<sup>2</sup> · Alfredo Berardelli<sup>3,4</sup> · Nicola Modugno<sup>5</sup> · Italo Stroppa<sup>6</sup> · Filippo Tamma<sup>7</sup> · Mariachiara Sensi<sup>8</sup> · Francesca Mancini<sup>9</sup> · Giovanni Cossu<sup>10</sup> · Alessandro Stefani<sup>11</sup> · Nicola Tambasco<sup>12</sup> · Alessandro Tessitore<sup>13</sup> · Giovanni Fabbrini<sup>3,4</sup> · Francesco E. Pontieri<sup>14</sup> · Paolo Solla<sup>15</sup> · Anna Rita Bentivoglio<sup>16,17</sup> · Cristoforo Comi<sup>18</sup> · Brigida Minafra<sup>19</sup> · Giulio Riboldazzi<sup>20</sup> · Donato Melchionda<sup>21</sup> · Tommaso Martino<sup>21</sup> · Leonardo Lopiano<sup>22</sup>

Published online: 3 June 2020  
© Springer-Verlag GmbH Austria, part of Springer Nature 2020

**Correction to: Journal of Neural Transmission**  
<https://doi.org/10.1007/s00702-020-02175-1>

The original version of this article unfortunately contained a mistake. Alfredo Berardelli and Giovanni Fabbrini affiliations were incorrect.

The original article can be found online at <https://doi.org/10.1007/s00702-020-02175-1>.

✉ Angelo Antonini  
angelo3000@yahoo.com

- <sup>1</sup> Parkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy
- <sup>2</sup> Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal Child Health, University of Genoa-IRCCS Ospedale Policlinico San Martino, Genova, Italy
- <sup>3</sup> Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy
- <sup>4</sup> IRCCS Neuromed, Pozzilli, Isernia, Italy
- <sup>5</sup> Parkinson Centre-IRCCS Neuromed, Pozzilli, Isernia, Italy
- <sup>6</sup> U.O. Dipartimentale di Endoscopia Digestiva Operativa e D'Urgenza, Policlinico Tor Vergata, Rome, Italy
- <sup>7</sup> Neurology Unit, Miulli Hospital, Acquaviva delle Fonti, BA, Italy
- <sup>8</sup> Neurology Unit, Hospital Sant'Anna, Cona, Ferrara, Italy
- <sup>9</sup> UO Neurologia e Stroke Unit e Laboratorio Neuroscienze, Istituto Auxologico San Luca, Milan, Italy
- <sup>10</sup> SC Neurologia e Stroke Unit, Azienda Ospedaliera Brotzu, Cagliari, Italy
- <sup>11</sup> UOSD Parkinson, Fondazione Policlinico Tor Vergata, Rome, Italy

The correct affiliation of Alfredo Berardelli and Giovanni Fabbrini and author group are given.

In Table 1 there is a little mistake. The mistake is included in the part of the table describing the “Reason to start LCIG”. The corrected Table 1 is placed in the following page.

- <sup>12</sup> Neurology Department, Perugia General Hospital and University of Perugia, Perugia, Italy
- <sup>13</sup> Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania, “Luigi Vanvitelli”, Naples, Italy
- <sup>14</sup> Department NESMOS, “Sapienza” University, Sant'Andrea Hospital, Rome, Italy
- <sup>15</sup> Neurology Unit, Policlinico Universitario Monserrato, Cagliari, Italy
- <sup>16</sup> Institute of Neurology, Università Cattolica del Sacro Cuore, Rome, Italy
- <sup>17</sup> Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- <sup>18</sup> Parkinson's Disease and Movement Disorders Centre, Neurology Unit, University of Piemonte Orientale, Novara, Italy
- <sup>19</sup> Parkinson's Disease and Movement Disorders Unit, IRCCS C. Mondino Foundation, Pavia, Italy
- <sup>20</sup> Parkinson's Disease and Movement Disorders Centre, Neurology Unit, ASST dei Sette Laghi, Varese, Italy
- <sup>21</sup> S.C. Neurology, Neuroscience Department, A.O.U. Ospedali Riuniti, University of Foggia, Foggia, Italy
- <sup>22</sup> Department of Neuroscience “Rita Levi-Montalcini”, University of Torino, Torino, Italy

**Table 1** Demographics, medical history, PD characteristics, symptoms, motor fluctuations, complications and quality of life (QoL) recorded at BL [mean  $\pm$  SD,  $N$ =(%)]

Gender	
Male	88 (55%)
Female	71 (45%)
Age (years)	69.1 $\pm$ 6.6
Weight (kg)	70.0 $\pm$ 12.5
BMI	25.3 $\pm$ 3.6
Medical history	
Cognitive decline (mild/moderate)	52 (33%)
Psychosis	7 (5%)
Depression	44 (28%)
Compulsive disorder	7 (5%)
Dementia	5 (3%)
Family history	
Parkinson disease	86 (54%)
Parkinsonism	2 (1%)
Tremor	8 (5%)
Other Parkinson syndromes	8 (5%)
Dementia	8 (5%)
PD characteristics	
Time since PD diagnosis (years)	13.6 $\pm$ 5.6
Time since fluctuations (years)	8.4 $\pm$ 4.0
Previous PD treatment	
Levodopa	98%
Dopamine agonist	79%
COMT inhibitors	54%
MAO-B inhibitors	41%
Amantadine	21%
Apomorphine Sc	5%
DBS-STN	3%
Other oral	5%
Severity stage	
Hoehn and Yahr "On"	2.6 $\pm$ 0.7
Hoehn and Yahr "OFF"	3.6 $\pm$ 0.8
PD symptoms	
Tremor [unilateral/bilateral]	90 (57%) [83 (52%)/7 (4%)]
Rigidity [unilateral/bilateral]	97 (61%) [83 (52%)/14 (9%)]
Bradykinesia [unilateral/bilateral]	111 (70%) [80 (52%)/31 (20%)]
Postural instability	31 (20%)
Hyposmia	11 (7%)
Anxiety	13 (8%)
Depression	31 (20%)
Apathy	6 (4%)
Others <sup>a</sup>	15 (9%)
Complications	
Pain	63 (42%)
Freezing	85 (5%)
Dystonia	48 (32%)
Fall	72 (47%)
Gait and walking disturbances	96 (63%)
Motor fluctuations	
UDDRS Part III total score in "On" ( $N$ =140)	28.0 $\pm$ 13.3
UDDRS Part III total score in "OFF" ( $N$ =131)	45.8 $\pm$ 13.2

**Table 1** (continued)

Complications of therapy	
UPDRS part-IV total score ( $N=133$ )	$8.8 \pm 2.9$
Quality of life	
PDQ-8 total score ( $N=61$ )	$17.0 \pm 8.0$
ADL ( $N=62$ )	$4.6 \pm 3.4$
PDQ-39 total score ( $N=39$ )	$36.7 \pm 20.2$
Reason to start LCIG	
Motor fluctuations	143 (90%)
Dyskinesia	86 (54%)
Prolonged OFF	105 (66%)
Others <sup>b</sup>	13 (8%)

TANDEM population ( $N=159$ )

Number of observations in efficacy assessments: UPDRS part-III “On” ( $N=140$ ), UPDRS part-III “OFF” ( $N=131$ ), UPDRS part-IV ( $N=133$ ), PDQ-8 ( $N=61$ ), ADL ( $N=62$ ) and PDQ-38 ( $N=39$ )

*PD* Parkinson’s disease, *ADL* activities of daily living, *QoL* quality of life, *UPDRS* Unified Parkinson’s Disease Rating Scale, *PDQ-8* 8-item Parkinson’s Disease Questionnaire, *PDQ-39* 39-item Parkinson’s Disease Questionnaire, *DBS-STN* deep brain stimulation of the subthalamic nucleus, *Sc* subcutaneous, *COMT* catechol-*O*-methyltransferase, *MAO-B* monoamine oxidase

<sup>a</sup>Asthenia, headache, pain, gait disturbances, visual disturbances, hypophonia

<sup>b</sup>Deep brain stimulation of the subthalamic nucleus, non-motor OFF, blepharospasm, dysphagia, dystonia, freezing, frequent falls

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.